Online inquiry

IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1642MR)

This product GTTS-WQ1642MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets F10&F9 gene. The antibody can be applied in Hemophilia A research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000504.4; NM_000133.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2159; 2158
UniProt ID P00742; P00740
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ1642MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ761MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AB0024
GTTS-WQ13509MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PRX002
GTTS-WQ14734MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SGN-19A
GTTS-WQ10411MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY2439821
GTTS-WQ15783MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ4251MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BIIB031
GTTS-WQ7490MR IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GC-1008
GTTS-WQ7494MR IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA GC-1008
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW